You are here: Home: Meet The Professors Vol. 4 Issue 2 : Faculty Disclosures

Faculty Affiliations

	Howard A Burris III, MD Director of Drug Development Sarah Cannon Research Institute Nashville, Tennessee		Daniel F Hayes, MD Professor of Internal Medicine Clinical Director, Breast Oncology Program Division of Hematology/ Oncology Department of Internal Medicine University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan
	Peter M Ravdin, MD, PhD Clinical Professor of Medicine The University of Texas Health Science Center at San Antonio San Antonio, Texas		George W Sledge Jr, MD Professor of Medicine Ballve-Lantero Professor of Oncology Indiana University Medical Center Indianapolis, Indiana

Medical Oncologist Community Panel

David M Dresdner, MD St Petersburg, Florida Philip Glynn, MD Springfield, Massachusetts Lowell L Hart, MD Fort Myers, Florida William N Harwin, MD Fort Myers, Florida

Carolyn B Hendricks, MD Bethesda, Maryland Atif M Hussein, MD Hollywood, Florida Dennis A Lowenthal, MD Short Hills, New Jersey Susan L Luedke, MD St Louis, Missouri

William G Reeves, MD Youngstown, Ohio Leonard J Seigel, MD Fort Lauderdale, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD, MS and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Burris — Consulting Fees: Genentech BioOncology, Novartis Pharmaceuticals; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Sanofi-Aventis. Dr Hayes — No financial interests or affiliations to disclose. Dr Ravdin — Consulting Fees: AstraZeneca Pharmaceuticals LP, Sanofi-Aventis; Ownership Interest: Adjuvant! Inc. Dr Sledge — Consulting Fees: Genentech BioOncology, Roche Laboratories Inc; Contracted Research: Sanofi-Aventis.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.